###### Strengths and limitations of this study

-   This study uses a large dataset (70% of Australian poisons centre calls), over a long period (2006--2016), to comprehensively describe child and adolescent self-poisoning in Australia.

-   Calls are coded by specialists in poisons information, and thus, coding of substances taken is of high quality and more sensitive than hospital coding.

-   The Pharmaceutical Benefits Scheme 10% sample is a nationwide dispensing dataset, allowing us to estimate psychotropic medicine use in this age group.

-   Retrospective study design.

-   Not all poisonings result in a call to a Poisons Information Centre, thus, our study does not capture all self-poisonings in this age group.

Introduction {#s1}
============

Rates of self-harm increase sharply during adolescence, especially in females. It is estimated that around 10% of adolescents have self-harmed at some point, with self-poisoning the most common form of hospitalised self-harm in children and adolescents.[@R1] Self-poisoning has a low case fatality rate,[@R2] however, self-poisoning episodes are often predictive of mental health problems later in life.[@R3] The risk of completed suicide in the year following self-poisoning is markedly increased relative to reference individuals and this increased risk persists over the following decade.[@R3] Suicide is the third most common cause of death among adolescents worldwide.[@R4] Evidence from the USA and UK suggests that rates of self-poisoning/self-harm in children and adolescents have increased at the beginning of this decade.[@R5] Two recent Australian studies have shown increases in emergency department presentations for the child and adolescent self-harm in New South Wales (NSW), 2010--2014,[@R8] and Victoria, 2008--2015.[@R9]

Like self-harm, use of psychotropics may act as a proxy measure for mental well-being. Internationally, rates of psychotropic medicine use in children and adolescents have been increasing.[@R10] From 2009 to 2012, antidepressant, antipsychotic and attention deficit hyperactivity disorder (ADHD) medicine use increased by 25%, 31% and 24%, respectively, in Australians under the age of 25.[@R13] Psychotropic medicines are commonly used in deliberate self-poisoning,[@R14] and there is some evidence that use of certain psychotropic medicines in people under 25 is associated with increased suicidality.[@R16]

There are limited data on more recent time trends in self-poisoning and psychotropic medicine use in young Australians. This study aims to characterise Australian trends in self-poisoning and psychotropic dispensing in young people. Specifically, we aim to: (1) evaluate trends in deliberate self-poisoning in Australians aged 5--19 years, 2006--2016, (2) identify substances most commonly used in self-poisoning by children and adolescents and (3) analyse trends in psychotropic medicine dispensing to children and adolescents, 2012--2016.

Methods {#s2}
=======

Design {#s2a}
------

This is a retrospective cohort study of self-poisonings and psychotropic dispensings in Australians aged 5--19 years. Poisons Information Centre (PIC) data provide up to date and detailed information on self-poisoning behaviours. Australia has four PICs, together providing nationwide poisoning advice to healthcare professionals and members of the public. We used data from the NSWPIC and Victorian PIC (VPIC), which together take approximately 70% of the nation's 200 000 yearly poisoning calls. For the purposes of this study, a 'child' is defined as someone aged 5--14 years, and an 'adolescent' is between the ages of 15 and 19 years (as PICs use these categories when coding calls).

We also used psychotropic dispensing data, as a separate proxy measure for mental well-being. For the purposes of this study, psychotropic pharmaceuticals included antidepressants, benzodiazepines, antipsychotics, psychostimulants and clonidine. Australia has a publicly funded universal healthcare system, with subsidised medicines available to citizens and permanent residents under the Pharmaceutical Benefits Scheme (PBS). We used PBS dispensing data from a random 10% sample of PBS-eligible Australians. This nationwide data source has been described in detail previously.[@R18] This is a standard dataset provided by the Australian Government Department of Human Services and is the gold standard for pharmacoepidemiology research in Australia.

Data sources {#s2b}
------------

### The NSWPIC and VPIC databases {#s2b1}

The NSWPIC and VPIC databases were searched from 2006 to 2016 for calls where the exposure type was 'intentional' (this includes deliberate self-poisoning, recreational use and intentional misuse). Calls were included if the patient's age category at the time of poisoning was coded as 'Child' or 'Adolescent'. Exact age was recorded in over 97% of cases (other calls were coded as either child or adolescent without a precise age specified).

PIC data were recoded by RC (poisons information specialist) to harmonise substance codes between the different centres. Substances were divided into broad categories for trend analysis: non-narcotic analgesics (paracetamol, aspirin, non-steroidal anti-inflammatory drugs), psychotropics (antidepressants, antipsychotics, anxiolytics/sedatives, psychostimulants), opioids (non-illicit), other prescription pharmaceuticals, other over-the-counter pharmaceuticals, gases (eg, carbon monoxide) and other non-pharmaceutical substances (including household products, chemicals, pesticides, plants).

We also categorised medicines taken in overdose into three categories based on the Australian Medicines Handbook Children's Dosing Companion (AMHCDC, July 2017 online version): approved in children, 'off-label, accepted' (not in manufacturer's product information (PI) but in the AMHCDC), and 'off-label, not accepted' (not in the PI or AMHCDC).

Since PICs often receive multiple calls about the one exposure (eg, family member, then triage nurse and doctor), these subsequent calls ('recalls') were excluded from the analysis. Note that these data relate to self-poisoning events, one individual may have repeated self-poisonings, and thus may be included several times in this dataset.

Intentional exposure counts (all ages) from NSWPIC and VPIC were also extracted to allow comparison to overall trends.

### PBS 10% sample {#s2b2}

We extracted psychotropic dispensings in people aged 5--19 years. Note that year of birth is perturbed 180 days so this provides only an estimate of age.

Prior to 2012, the PBS 10% sample only captured dispensings where the government paid a contribution. For cheaper medicines, some beneficiaries pay the full cost of the medicine (defined as 'under copayment'), and these dispensings were not captured prior to 2012.[@R18] Due to these data capture changes, we extracted dispensings from July 2012 to June 2016 for in-depth analysis. Longer term data (2006--2015, excluding under copayment dispensings) were extracted for the same medicines to allow comparison to longer term trends.

### Data analysis {#s2b3}

We analysed time trends in poisonings using negative binomial regression with a log link function. We analysed self-poisoning by individual age at the time of the episode. We also created the year of birth cohorts by estimating a birth year from age at the time of call (online [supplementary table 1](#SP1){ref-type="supplementary-material"}). Poisonings per birth year cohort per year were plotted graphically.[@R19]
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For our primary analysis of PBS data (July 2012 to June 2016), we estimated the monthly prevalence of psychotropic use (by class, subclass and individual medicine) for individuals aged 5--14 years, 15--19 years and both groups combined (5--19 years). A prevalence was estimated from the number of individuals with at least one dispensing of a psychotropic class, subclass or specific medicine in a given month. We reported the prevalence as the number of users per 10 000 population, using population estimates obtained from the Australian Bureau of Statistics (using national population figures, as the PBS 10% sample is a nationwide database). We also used linear regression analysis to calculate slope changes and 95% CIs. Data were not shown if there were less than 30 persons in the 10% sample dispensed that subclass or medicine in at least 1 month examined. For graphical presentations of monthly data, 12-month rolling averages were used to smooth seasonality in the PBS data (due to medicine stockpiling at the end of each year).[@R18] For our secondary analysis (2006--2015), we calculated yearly prevalence (ie, the number of individuals with at least one dispensing of a psychotropic class, subclass or specific psychotropic in a given year/10 000 population).

Data analysis and presentation was performed with GraphPad Prism V.7.00 (GraphPad Software, La Jolla, California, USA), Tableau Desktop V.9.3 (Tableau Software, Seattle, Washington, USA) and SAS V.9.4 (SAS).

Patient and public involvement {#s2c}
------------------------------

This was a retrospective review of routinely collected data. Patients and the public were not involved in the design or the recruitment of the study.

Data access approvals {#s2d}
---------------------

Access to the PBS 10% sample was approved by the Australian Department of Human Services External Request Evaluation Committee.

Results {#s3}
=======

Intentional poisonings {#s3a}
----------------------

In the 11-year study period, the NSWPIC and VPIC databases recorded 8053 intentional poisonings in individuals aged 5--14 years and 25 448 intentional poisonings in those aged 15--19 years (total 33 501 poisonings in people aged 5--19 years). Numbers of self-poisonings in those aged 5--19 years increased by 8.39% per year (95% CI 6.08% to 10.74%, p\<0.0001), with an overall increase of 98%, 2006--2016 ([figure 1](#F1){ref-type="fig"}). Self-poisonings in children increased by 9.00% per year (95% CI 6.26% to 11.81%, p\<0.0001), overall 107%, 2006--2016. Adolescent self-poisonings increased by 8.21% per year, (95% CI 5.96% to 10.5%, p\<0.0001) or 96% over the study period. By comparison, we observed an overall increase of 15% in self-poisoning in persons aged 20 years and over, 2006--2016. In children and adolescents, self-poisonings for females outnumbered those for males by 3--1 ([figure 1](#F1){ref-type="fig"}). Self-poisoning in females increased by 108% in total, 9.21% per year, (95% CI 6.63% to 11.86%, p\<0.0001), while in males increased by 72% in total, 6.03% per year (95% CI 3.96% to 8.14%, p\<0.0001).

![Trends in intentional poisonings in children and adolescents reported to the NSWPIC and VPIC, 2006--2016. NSWPIC, New South Wales Poisons Information Centre; VPIC, Victorian Poisons Information Centre.](bmjopen-2018-026001f01){#F1}

Self-poisoning increased dramatically and is consistently higher in those born after 1997 ([figure 2](#F2){ref-type="fig"}), indicating a birth cohort effect. Overall, substances most commonly used in self-poisoning episodes included analgesics (including those available without a prescription) and psychotropics ([table 1](#T1){ref-type="table"}); many exposures were to medicines where use in children/adolescents is 'off-label'. Time trends in exposures to agents broken down by broad substance classes (online [supplementary figure 1](#SP1){ref-type="supplementary-material"}) show large increases in poisonings with psychotropics and non-narcotic analgesics.

![Number of intentional poisonings by birth year cohort at ages 5--19 years, 2006--2016.](bmjopen-2018-026001f02){#F2}

###### 

The most common substances ingested in child and adolescent self-poisoning events to NSWPIC and VPIC, 2006--2016 (n=33 501)

                                                   5--14 years   15--19 years   Grand total
  ------------------------------------------------ ------------- -------------- -------------
  *Paracetamol*\*                                  1901          6028           7929
  *Ibuprofen*\*                                    785           2782           3567
  Fluoxetine                                       428           1663           2091
  Ethanol                                          207           1786           1993
  Quetiapine                                       313           1534           1847
  *Paracetamol/opioid*\*                           266           1257           1523
  Sertraline                                       166           1315           1481
  Escitalopram                                     91            762            853
  *Cough/cold preparations: paracetamol based*\*   129           704            833
  Diazepam                                         113           718            831
  Methylphenidate                                  317           500            817
  *Promethazine*\*                                 168           549            717
  *Caffeine*\*                                     200           463            663
  **Venlafaxine**                                  61            476            537
  *Aspirin/acetylsalicylic acid*\*                 112           425            537
  Valproic acid                                    114           398            512
  Clonidine                                        221           259            480
  Olanzapine                                       64            408            472
  **Temazepam**                                    63            405            468
  *Ibuprofen, combinations*\*                      82            365            447
  *Bleach*\*                                       138           304            442
  Fluvoxamine                                      86            349            435
  Risperidone                                      146           286            432
  Mirtazapine                                      60            343            403
  Citalopram                                       62            326            388
  Miscellaneous medicine^%^                        88            276            364
  Oxycodone                                        47            306            353
  *Herbal preparations*\*                          82            265            347
  **Desvenlafaxine**                               26            314            340
  Ecstasy (MDMA)                                   20            310            330
  Amitriptyline                                    66            253            319
  Marijuana                                        47            264            311
  *Doxylamine\**                                   52            253            305
  Amphetamines (illicit)                           23            248            271
  Alprazolam                                       44            221            265
  *Diclofenac\**                                   59            204            263

Shaded rows: prescription medicine not approved for children in manufacturer product information.

Bold: not approved for children in manufacturer product information and not in Australian Medicines Handbook Children's Dosing Companion (see the Methods section for further details).

Italics\*: available over the counter/unscheduled.

%: includes cases where the medication was unknown, or purchased overseas/over the internet (not marketed in Australia).

MDMA, methylenedioxymethamphetamine; NSWPIC, New South Wales Poisons Information Centre; VPIC, Victorian Poisons Information Centre.

Psychotropic dispensing {#s3b}
-----------------------

We observed increases in the number of individuals aged 5--19 dispensed specific psychotropic medicines. From July 2012 to June 2016, selective serotonin reuptake inhibitor (SSRI) dispensing increased 40% and 35% in those aged 5--14 and 15--19, respectively ([table 2](#T2){ref-type="table"}, [figure 3](#F3){ref-type="fig"}). Males received \~60% of antidepressants in the age group of 5--14 years. Conversely, in those aged 15--19, females received 65% of antidepressant dispensings ([table 2](#T2){ref-type="table"}, [figure 3](#F3){ref-type="fig"}). Fluoxetine was the most dispensed SSRI across both genders and age groups (increasing 54% and 44% in those aged 5--14 and 15--19, respectively). Escitalopram, fluvoxamine and sertraline were also commonly used in the older age group. Use of other antidepressant classes was lower, although venlafaxine and mirtazapine increased 27% and 34%, respectively, in those aged 15--19 ([table 2](#T2){ref-type="table"}). Males received \~80% of antipsychotics in the age group of 5--14 years, decreasing to \~60% in the age group of 15--19 years ([table 3](#T3){ref-type="table"}). Trends in antipsychotic dispensing in people aged 5--19 show that risperidone and quetiapine are the most used, with a 19% increase in risperidone dispensing ([table 3](#T3){ref-type="table"}). In people aged 5--19 years, 80% of ADHD medication dispensing was to males. ADHD medicine dispensing has increased 14% in people aged 5--19, with clonidine and methylphenidate dispensing increasing 26% and 17%, respectively. Conversely, dispensing of benzodiazepines to this age group is relatively uncommon and has decreased by 6%. Females were dispensed \~60% of benzodiazepines. Longer term trends (2006--2015), without under copayment data are displayed in online [supplementary figures 2--4](#SP1){ref-type="supplementary-material"}, indicating that these recent changes are largely an extension of longer term trends.

![Rolling average of SSRI prevalence (persons/10 000 population/month), in females and males aged 5--14 years (A and B, respectively), and females and males aged 15--19 years (C and D, respectively), July 2012 to June 2016. Data were not shown for medicines where there were \<30 persons in 10% sample on that class in at least 1 month examined. SSRI, selective serotonin reuptake inhibitor.](bmjopen-2018-026001f03){#F3}

###### 

Time trends and gender distribution antidepressant dispensing prevalence (persons/10 000 population/month) in Australians aged 5--19 years

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                     \% Female\           \% Female\           Monthly ave. July 12 to June 13   Monthly ave. July 15 to June 16   Rate of increase per month (95% CI)\*   \% Change, 2012/2013 to 2015/2016
                     July 12 to June 13   July 15 to June 16                                                                                                               
  ------------------ -------------------- -------------------- --------------------------------- --------------------------------- --------------------------------------- -----------------------------------
  5--14 years                                                                                                                                                              

   Antidepressants   38                   41                   29.00                             37.99                             0.22 (0.13 to 0.3)                      **31**

   SSRIs             38                   41                   23.15                             32.41                             0.23 (0.16 to 0.3)                      **40**

   Citalopram        †                    †                    †                                 †                                                                         

   Escitalopram      49                   45                   1.34                              1.94                              0.014 (0.0065 to 0.021)                 **45**

   Fluoxetine        37                   39                   12.34                             19.02                             0.17 (0.13 to 0.21)                     **54**

   Fluvoxamine       36                   43                   3.54                              4.82                              0.029 (0.018 to 0.041)                  **36**

   Paroxetine        †                    †                    †                                 †                                                                         

   Sertraline        38                   43                   5.11                              6.07                              0.02 (0.0038 to 0.035)                  **19**

   SNRI              †                    †                    †                                 †                                                                         

   NaSSA             †                    †                    †                                 †                                                                         

   TCA               35                   41                   4.73                              4.21                              −0.019 (−0.028 to −0.01)                **−11**

  15--19 years                                                                                                                                                             

   Antidepressants   65                   65                   192.91                            250.23                            1.4 (1 to 1.8)                          **30**

   SSRI              65                   65                   147.63                            198.60                            1.3 (1 to 1.5)                          **35**

   Citalopram        67                   66                   9.69                              8.85                              −0.033 (−0.057 to −0.0093)              **−9**

   Escitalopram      70                   68                   30.49                             39.62                             0.21 (0.12 to 0.29)                     **30**

   Fluoxetine        63                   63                   55.68                             80.35                             0.66 (0.58 to 0.73)                     **44**

   Fluvoxamine       56                   57                   11.09                             15.89                             0.12 (0.097 to 0.14)                    **43**

   Paroxetine        62                   66                   3.69                              5.59                              0.049 (0.037 to 0.06)                   **51**

   Sertraline        66                   66                   37.79                             49.83                             0.31 (0.24 to 0.38)                     **32**

   SNRI              70                   70                   29.31                             33.42                             0.071 (−0.02 to 0.16)                   14

   Desvenlafaxine    70                   70                   14.39                             16.13                             0.027 (−0.018 to 0.072)                 12

   Duloxetine        68                   71                   6.20                              6.33                              −0.0028 (−0.025 to 0.019)               2

   Venlafaxine       72                   70                   8.65                              10.99                             0.05 (0.022 to 0.079)                   **27**

   NaSSA             52                   54                   8.28                              11.01                             0.067 (0.04 to 0.095)                   **33**

   Mirtazapine       51                   54                   8.19                              10.98                             0.069 (0.042 to 0.096)                  **34**

   TCA               63                   65                   10.14                             11.28                             0.021 (−0.0023 to 0.045)                11

  5--19 years                                                                                                                                                              

   Antidepressants   59                   59                   84.82                             108.86                            0.58 (0.41 to 0.76)                     **28**

   SSRI              59                   59                   65.54                             87.90                             0.56 (0.43 to 0.69)                     **34**

   Citalopram        65                   64                   3.80                              3.35                              −0.016 (−0.026 to −0.0067)              **−12**

   Escitalopram      69                   66                   11.26                             14.52                             0.073 (0.042 to 0.1)                    **29**

   Fluoxetine        55                   55                   27.10                             39.50                             0.33 (0.28 to 0.37)                     **46**

   Fluvoxamine       48                   52                   6.11                              8.51                              0.057 (0.044 to 0.071)                  **39**

   Paroxetine        61                   65                   1.41                              1.95                              0.014 (0.0092 to 0.018)                 **38**

   Sertraline        60                   62                   16.24                             20.68                             0.11 (0.077 to 0.14)                    **27**

   SNRI              69                   69                   10.57                             11.84                             0.02 (−0.013 to 0.053)                  12

   Desvenlafaxine    69                   69                   5.08                              5.69                              0.0091 (−0.0074 to 0.026)               12

   Duloxetine        66                   70                   2.27                              2.26                              −0.0026 (−0.01 to 0.0053)               0

   Venlafaxine       70                   68                   3.21                              3.89                              0.014 (0.0037 to 0.024)                 **21**

   NaSSA             56                   52                   3.14                              4.08                              0.023 (0.013 to 0.033)                  **30**

   Mirtazapine       51                   53                   3.11                              4.07                              0.023 (0.013 to 0.033)                  **31**

   TCA               49                   55                   6.57                              6.57                              −0.0066 (−0.018 to 0.0051)              0
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bolded % change figures indicate significant changes (judged by a 95% CI that does not cross zero).

\*Based on regression line to account for monthly fluctuation.

†Data were not shown in medicines/classes where there were \<30 persons in 10% sample on that class in at least 1 month examined.

NaSSA, noradrenergic and specific serotonergic antidepressant; SNRI, serotonin--norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.

###### 

Time trends and gender distribution in antipsychotic, benzodiazepine and ADHD medication dispensing prevalence (persons/10 000 population/month) in Australians aged 5--19 years

                      \% Female, July 12 to June 13   \% Female, July 15 to June 16   Monthly ave. July 12 to June 13   Monthly ave. July 15 to June 16   Rate of increase per month (95% CI)\*   \% Change, 2012/2013 to 2015/2016
  ------------------- ------------------------------- ------------------------------- --------------------------------- --------------------------------- --------------------------------------- -----------------------------------
  5--14 years                                                                                                                                                                                     
   Antipsychotics     20                              19                              13.97                             15.82                             0.041 (0.016 to 0.067)                  **13**
   Typical            †                               †                               †                                 †                                                                         
   Atypical           20                              19                              13.38                             15.31                             0.044 (0.02 to 0.068)                   **14**
   Risperidone        17                              17                              11.86                             13.85                             0.048 (0.029 to 0.067)                  **17**
   Olanzapine         †                               †                               †                                 †                                                                         
   Quetiapine         †                               †                               †                                 †                                                                         
   Aripiprazole       †                               †                               †                                 †                                                                         
   Benzodiazepines    54                              46                              1.72                              1.65                              −0.0041 (−0.01 to 0.0021)               −4
   Diazepam           †                               †                               †                                 †                                                                         
   Temazepam          †                               †                               †                                 †                                                                         
   ADHD medications   18                              20                              106.59                            123.13                            0.39 (0.23 to 0.55)                     **16**
   Atomoxetine        21                              20                              6.01                              5.86                              −0.0084 (−0.02 to 0.0038)               −2
   Clonidine          22                              24                              12.99                             16.58                             0.091 (0.071 to 0.11)                   **28**
   Dexamfetamine      15                              18                              7.87                              7.41                              −0.016 (−0.027 to −0.0044)              **−6**
   Methylphenidate    18                              19                              88.1                              103.04                            0.36 (0.21 to 0.5)                      **17**
  15--19 years                                                                                                                                                                                    
   Antipsychotics     39                              40                              30.88                             34.01                             0.056 (0.0063 to 0.11)                  **10**
   Typical            †                               †                               †                                 †                                                                         
   Atypical           39                              40                              29.31                             32.52                             0.06 (0.012 to 0.11)                    **11**
   Risperidone        19                              25                              11.27                             13.77                             0.073 (0.057 to 0.089)                  **22**
   Olanzapine         35                              45                              5.15                              4.74                              −0.017 (−0.033 to −0.00035)             **−8**
   Quetiapine         63                              61                              10.23                             9.70                              −0.033 (−0.064 to −0.0021)              **−5**
   Aripiprazole       †                               †                               †                                 †                                                                         
   Benzodiazepines    60                              60                              15.24                             14.42                             −0.036 (−0.082 to 0.011)                −5
   Diazepam           57                              56                              7.58                              8.21                              0.012 (−0.016 to 0.04)                  8
   Temazepam          61                              64                              5.49                              4.43                              −0.033 (−0.052 to −0.013)               **−19**
   ADHD medications   22                              23                              70.79                             77.52                             0.22 (0.11 to 0.33)                     **10**
   Atomoxetine        16                              28                              4.34                              4.24                              −0.0016 (−0.012 to 0.0085)              −2
   Clonidine          22                              25                              7.96                              9.46                              0.046 (0.027 to 0.065)                  **19**
   Dexamfetamine      23                              23                              8.88                              6.32                              −0.067 (−0.082 to −0.052)               **−29**
   Methylphenidate    21                              22                              53.59                             62.32                             0.27 (0.17 to 0.37)                     **16**
  5--19 years                                                                                                                                                                                     
   Antipsychotics     30                              30                              19.73                             21.89                             0.043 (0.011 to 0.075)                  **11**
   Typical            30                              32                              1.01                              0.93                              −0.0032 (−0.0061 to −0.00031)           **−8**
   Atypical           30                              30                              18.81                             21.06                             0.046 (0.015 to 0.077)                  **12**
   Risperidone        18                              19                              11.66                             13.82                             0.056 (0.043 to 0.07)                   **19**
   Olanzapine         35                              46                              1.95                              1.73                              −0.0082 (−0.014 to −0.002)              **−11**
   Quetiapine         61                              60                              4.02                              3.68                              −0.017 (−0.029 to −0.0046)              **−8**
   Aripiprazole       33                              37                              1.06                              1.54                              0.013 (0.01 to 0.016)                   **45**
   Benzodiazepines    59                              57                              6.33                              5.92                              −0.017 (−0.036 to 0.0013)               −6
   Diazepam           58                              54                              3.18                              3.37                              0.0023 (−0.009 to 0.013)                6
   Temazepam          59                              63                              2.01                              1.60                              −0.013 (−0.02 to −0.0056)               **−20**
   ADHD medications   19                              21                              94.40                             107.90                            0.34 (0.23 to 0.45)                     **14**
   Atomoxetine        20                              22                              5.44                              5.32                              −0.0058 (−0.015 to 0.003)               −2
   Clonidine          22                              24                              11.28                             14.21                             0.077 (0.062 to 0.092)                  **26**
   Dexamfetamine      18                              20                              8.21                              7.05                              −0.033 (−0.044 to −0.022)               **−14**
   Methylphenidate    19                              20                              76.35                             89.44                             0.34 (0.23 to 0.44)                     **17**

Bolded % change figures indicate significant changes (judged by a 95% CI that does not cross zero).

\*Based on regression line to account for monthly fluctuation.

†Data were not shown in medicines/classes where there were \<30 persons in 10% sample on that class in at least 1 month examined.

ADHD, attention deficit hyperactivity disorder.

Discussion {#s4}
==========

There was a substantial increase in child and adolescent self-poisonings in the poisons centre databases over the 11-year study period. There appears to be a cohort effect, with those born after 1997 largely accounting for the increase in self-poisonings in the PIC dataset. Young females were over-represented in self-poisoning events, and the rate of increase was higher in females. The poisons most commonly used reflect the substances widely available in the community (such as household products and over-the-counter medicines) and substances commonly prescribed to children/adolescents. Psychotropic prescribing in children and adolescents has increased. In particular, SSRI prescribing has increased substantially. There is substantial overlap between the most dispensed psychotropics and medicines most commonly used in self-poisoning episodes.

Strengths and limitations {#s4a}
-------------------------

These results should be viewed in light of the strengths and limitations of this study. As discussed above, there have been recent reports of increases in adolescent self-harm presentations to emergency departments in NSW and Victoria (Australia's two most populous states). Hospital presentation data have limited sensitivity, and many self-poisonings may be coded as the presenting symptom.[@R20] Even when self-poisonings are identified, the agents involved cannot be well classified with clinical coding systems (such as The International Statistical Classification of Diseases and Related Health Problems, tenth revision (ICD-10) and Systematized Nomenclature of Medicine - Clinical Terms (SNOMED-CT)), and are generally coded under broad pharmacological groups. PIC data provide up-to-date data on self-poisonings in Australia with detailed capture of substances involved. Substances are coded in real time by specialists in poisons information (pharmacists and pharmacologists with postgraduate toxicology training) to a high standard. Capture of substances taken in overdose is much more detailed than routinely collected hospital presentation/admission data. Coding of exposure intent has been stable with time, with a categorisation of exposure intent (accidental, intentional) collected reliably since the early 1980s. Each call is reviewed within 12 hours by a colleague to further enhance accuracy. In addition, the increases observed in this study are on the background of decreasing overall calls to PICs,[@R21] and thus could not be explained by increased service utilisation. There have been no changes in referral practices/PIC utilisation that could explain a surge in calls.

Another strength of this study is its capture of over a decade's worth of data from two of Australia's poisons centres, amounting to \~70% of the nation's poisoning calls. This includes almost complete capture of poisons calls for the South East of Australia, plus some calls from the rest of the nation (due to the on-call structure shared by Australian PICs). NSWPIC and VPIC receive calls from members of the public and healthcare professionals across Australia and thus may provide better estimates of trends than studies conducted out of single hospitals. However, this is not a complete capture of all child/adolescent poisonings as calls to the PIC are voluntary, some hospitals may not call a PIC when a poisoning case presents, particularly those with local toxicology services or those staffed by experienced emergency physicians. Thus, this represents a conservative estimate of actual incidences of self-poisoning.

PBS data enable analysis of trends in the medicine dispensing on a nationwide scale but does not capture private scripts. However, it is estimated that private scripts account for less than 10% of dispensings in Australia.[@R22] Due to PBS data capture changes, our primary analysis was on dispensings from 2012 onwards.

Comparison with other studies {#s4b}
-----------------------------

This study signals a concerning increase in child/adolescent self-poisoning in Australia. Similar findings have been reported elsewhere in the world[@R5] indicating that this may be a global trend. A 2015 global burden of disease study ranked the top 25 causes of death worldwide in children. Globally, in children 10--14 years, self-harm was ranked 13th and 12th in girls and boys, respectively. A similar picture is seen globally in adolescents aged 15--19 years, where self-harm is ranked second and third in females and males, respectively. Self-harm was not in the top 25 causes of death in children aged 5--9 years.[@R24] Thus, self-harm is a substantial contributor to disease burden in children and adolescents worldwide. Any increase on this high base will have substantial overall effects on public health.

We have demonstrated large increases in certain psychotropic dispensings in those aged 5--19 years, particularly in antidepressants and antipsychotics. Unsurprisingly, psychotropics were commonly taken in overdose by this age group. Karanges *et al* recently described trends in psychotropic medicine use in Australians, 2009--2012. Dispensings of antidepressants and antipsychotics in children 10--14 years of age increased at a faster rate than in any other age group (35.5% and 49.1%, respectively).[@R13] This increased prescribing is not a uniquely Australian trend, with increases in antipsychotic use also documented in the USA[@R10] and the UK.[@R12] Use of antidepressants in children has remained stable in the USA, however, is increasing in the UK.[@R11] In Canada, antipsychotic use in children 18 and under increased fourfold, 1998--2008, with the largest increases in those aged 7--18 years.[@R25] In Denmark, psychotropic use in children 0--17 years increased ninefold, 1996--2010 (twofold increase when adjusting for increasing patient numbers).[@R26] A review of international trends in psychotropic medication use in children and adolescents found a general trend in many countries of increasing prescription rates.[@R27] This increase in utilisation is despite only limited evidence for efficacy in these age groups, and concerns regarding potentially increased risk of suicidal ideation and self-harm.[@R17]

Implications and future directions {#s4c}
----------------------------------

For those seen in the hospital, the estimated rate of repetition of non-fatal deliberate self-harm is 16% at 1 year, while a rate of suicide is 1.6% at 1 year and 3.9% at 5 years.[@R28] A recent study of completed suicides in England in people under 20 reported that more than half had previously self-harmed.[@R29] Thus, the patients in our study are at risk of repetition and completed suicide later in life.

The striking cohort effect observed here raises many questions about what is driving this trend. One could speculate that recent technological advancements have a role. Rising internet, social media and smartphone usage among young people could impact on mental health and responses to distress. The percentage of Australian teens who use a smartphone has increased from 23% to 80%, 2011--2015 (similar percentages are seen in teenagers in the USA and UK).[@R30] Increasing rates of self-harm could be due to increased mental illness in this population or changing behavioural responses in this cohort. Self-harm and suicidal contagion is a well-documented phenomenon. New media (eg, prosuicide websites normalising self-harm) could facilitate this contagion. Cyberbullying and internet use, in general, has been found to correlate with self-harm, suicide and mental illness.[@R31] Conversely, the internet may exert positive effects on young people at risk of self-harm, and there is great potential in new media for promoting positive mental health and coping strategies.[@R31]

People who self-poison often do this with medicines prescribed for them.[@R14] Of the most common substances involved in self-poisoning listed in [table 1](#T1){ref-type="table"}, there is considerable overlap with leading psychotropics dispensed ([tables 2 and 3](#T2 T3){ref-type="table"}), including fluoxetine, quetiapine, sertraline, escitalopram, methylphenidate, venlafaxine, fluvoxamine, risperidone, olanzapine and desvenlafaxine. Given the potential increase in suicidal ideation and behaviours in young people taking SSRIs, serotonin--norepinephrine reuptake inhibitors and ADHD medicines,[@R16] this could be a potential contributor to increasing self-poisoning attempts. Many of these medicines (including venlafaxine, desvenlafaxine) are not recommended in children according to current guidelines, and observed increases may be a result of marketing practices.[@R13] However, our results show some attempt to adhere to guidelines. Fluoxetine is the first-line treatment for depression in children and adolescents, and is the most prescribed antidepressant in this age group.

Given that there is little evidence for the efficacy of most psychotropics in this age group, their prescription should be carefully considered. If a psychotropic is prescribed, where possible, agents that are toxic in overdose (eg, citalopram, escitalopram, amisulpride,[@R32] venlafaxine[@R33] and quetiapine[@R34]) should be avoided. Prescribers should be vigilant for signs of anxiety or depression in their patients and keep medicine supplies to a minimum when prescribing to patients believed to be at risk of self-harm.

Importantly, we observed high rates of poisonings with readily available over-the-counter medicines, with paracetamol and ibuprofen being the top two substances used in self-poisonings in this age group. When compared with adults (aged 20 and over), children and adolescents are more likely to use over-the-counter medicines in intentional poisonings.[@R35] Paracetamol poisoning is the leading cause of acute liver failure in Western countries.[@R36] In Australia, paracetamol can be in 100×500 mg (50 g) and 96×665 mg (modified release, \~64 g) packs in pharmacies and 20×500 mg packs (10 g) outside of pharmacies. Previous studies have demonstrated that paracetamol overdoses are often impulsive and involve the use of paracetamol present in the home.[@R37] In 1998, the UK restricted paracetamol pack sizes in response to increasing overdoses, liver transplants and deaths. Sales were restricted to 16 g within pharmacies or 8 g outside of pharmacies. This legislation appears effective, with a subsequent reduction in large overdoses, liver unit admissions and deaths in England and Wales.[@R38] Although we did not assess outcomes of the paracetamol poisonings in our sample, similar means restriction in Australia could be implemented to reduce harm from paracetamol overdose.

The increase in self-poisoning and psychotropic use in this cohort raises three possibilities: (1) psychotropic prescribing predates self-poisoning and may increase suicidal ideation/self-harm tendencies; (2) psychotropic medicines are being prescribed following a self-harm attempt and (3) unrelated increase in self-poisoning and psychotropic medicines as independent markers of mental distress in this cohort. These are long-standing issues but our data demonstrate that it is increasingly important that these relationships are better characterised. Interestingly, males received the majority of antidepressant dispensings in the age group of 5--14 years, and yet females in this age group were more likely to self-poison, providing some information to support point (3) above, at least in younger children. Future studies using linked data to better characterise the relationship between psychotropic prescribing and self-harm/suicide could provide valuable insights into which of these three explanations is most likely.

Conclusion {#s5}
==========

There has been a steep increase in self-poisonings in Australian children and adolescents, particularly since 2011. This confirms that trends seen in the UK and USA are not confined to these particular countries, possibly indicating a global phenomenon. This could foretell increases in suicide rates, and signals a generation that may require a different approach to build coping strategies and resilience.
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